No Surgical Innovation Without Evaluation: Evolution and Further Development of the IDEAL Framework and Recommendations.


Journal

Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354

Informations de publication

Date de publication:
02 2019
Historique:
pubmed: 27 4 2018
medline: 15 11 2019
entrez: 27 4 2018
Statut: ppublish

Résumé

To update, clarify, and extend IDEAL concepts and recommendations. New surgical procedures, devices, and other complex interventions need robust evaluation for safety, efficacy, and effectiveness. Unlike new medicines, there is no internationally agreed evaluation pathway for generating and analyzing data throughout the life cycle of surgical innovations. The IDEAL Framework and Recommendations were designed to provide this pathway and they have been used increasingly since their introduction in 2009. Based on a Delphi survey, expert workshop and major discussions during IDEAL conferences held in Oxford (2016) and New York (2017), this article updates and extends the IDEAL Recommendations, identifies areas for future research, and discusses the ethical problems faced by investigators at each IDEAL stage. The IDEAL Framework describes 5 stages of evolution for new surgical therapeutic interventions-Idea, Development, Exploration, Assessment, and Long-term Study. This comprehensive update proposes several modifications. First, a "Pre-IDEAL" stage describing preclinical studies has been added. Second we discuss potential adaptations to expand the scope of IDEAL (originally designed for surgical procedures) to accommodate therapeutic devices, through an IDEAL-D variant. Third, we explicitly recognise the value of comprehensive data collection through registries at all stages in the Framework and fourth, we examine the ethical issues that arise at each stage of IDEAL and underpin the recommendations. The Recommendations for each stage are reviewed, clarified and additional detail added. The intention of this article is to widen the practical use of IDEAL by clarifying the rationale for and practical details of the Recommendations. Additional research based on the experience of implementing these Recommendations is needed to further improve them.

Sections du résumé

OBJECTIVE
To update, clarify, and extend IDEAL concepts and recommendations.
BACKGROUND
New surgical procedures, devices, and other complex interventions need robust evaluation for safety, efficacy, and effectiveness. Unlike new medicines, there is no internationally agreed evaluation pathway for generating and analyzing data throughout the life cycle of surgical innovations. The IDEAL Framework and Recommendations were designed to provide this pathway and they have been used increasingly since their introduction in 2009. Based on a Delphi survey, expert workshop and major discussions during IDEAL conferences held in Oxford (2016) and New York (2017), this article updates and extends the IDEAL Recommendations, identifies areas for future research, and discusses the ethical problems faced by investigators at each IDEAL stage.
METHODS
The IDEAL Framework describes 5 stages of evolution for new surgical therapeutic interventions-Idea, Development, Exploration, Assessment, and Long-term Study. This comprehensive update proposes several modifications. First, a "Pre-IDEAL" stage describing preclinical studies has been added. Second we discuss potential adaptations to expand the scope of IDEAL (originally designed for surgical procedures) to accommodate therapeutic devices, through an IDEAL-D variant. Third, we explicitly recognise the value of comprehensive data collection through registries at all stages in the Framework and fourth, we examine the ethical issues that arise at each stage of IDEAL and underpin the recommendations. The Recommendations for each stage are reviewed, clarified and additional detail added.
CONCLUSIONS
The intention of this article is to widen the practical use of IDEAL by clarifying the rationale for and practical details of the Recommendations. Additional research based on the experience of implementing these Recommendations is needed to further improve them.

Identifiants

pubmed: 29697448
doi: 10.1097/SLA.0000000000002794
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

211-220

Subventions

Organisme : Chief Scientist Office
ID : HSRU1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K025643/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S001751/1
Pays : United Kingdom
Organisme : FDA HHS
ID : U01 FD005478
Pays : United States

Auteurs

Allison Hirst (A)

Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.

Yiannis Philippou (Y)

Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.

Jane Blazeby (J)

Bristol Centre for Surgical Research, University of Bristol, Bristol, UK.

Bruce Campbell (B)

University of Exeter Medical School, Exeter, UK.

Marion Campbell (M)

Health Services Research Unit, University of Aberdeen, Aberdeen, UK.

Joshua Feinberg (J)

Maimonides Medical Center, Brooklyn, NY.

Maroeska Rovers (M)

Radboud University Medical Center, Nijmegen, The Netherlands.

Natalie Blencowe (N)

Bristol Centre for Surgical Research, University of Bristol, Bristol, UK.

Christopher Pennell (C)

Maimonides Medical Center, Brooklyn, NY.

Tom Quinn (T)

Faculty of Health, Social Care and Education, Kingston University and St George's, University of London, London, UK.

Wendy Rogers (W)

Department of Philosophy and Department of Clinical Medicine, Macquarie University, Sydney, Australia.

Jonathan Cook (J)

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

Angelos G Kolias (AG)

Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's Hospital and University of Cambridge, Cambridge, UK.
Surgery Theme, Cambridge Clinical Trials Unit, Cambridge, UK.

Riaz Agha (R)

Department of Plastic Surgery, Guy's and St. Thomas' NHS Foundation Trust, London, UK.

Philipp Dahm (P)

Department of Urology, Minneapolis VAMC and University of Minnesota, Minneapolis MN.

Art Sedrakyan (A)

Weill Cornell Medical College, New York, NY.

Peter McCulloch (P)

Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH